Centro Studi GISED

Go to content
Change language  EN IT


Centro Studi GISED was established in 2002 as a nonprofit organisation to develop independent clinical research in Dermatology and to promote an Evidence Based approach to the clinical management of skin disorders . Initially, activities were mainly focused on the coordination of the research projects of the Italian Group for Epidemiologic Research in Dermatology (GISED). Subsequently, they expanded to embrace any kind of clinical research, medical humanities, and health education.

In 2003, Centro Studi GISED got formal recognition for its activity and mandate by Regione Lombardia being entered in the Enterprise Registry (Registro delle Imprese) of the Bergamo Chamber of Commerce with number 2096.

In October 2003, Centro Studi GISED signed an agreement with the Regional Hospital, Ospedali Riuniti di Bergamo, and established its headquarter at the Department of Dermatology of the same Hospital.

Since 2003, following an agreement with the University of Milan, Centro Studi GISED is participating in the Inter-universitary Centre Thomas Chalmers for the development of systematic reviews and their implementation in clinical practice.


Answers from the Dermatologist

Dermatology category: Herpes zoster

Answers from the DermatologistQuestion: Hi, my fatherís 72 and in august 2002 he contracted herpes zoster. After having seen various doctors, without results, we have been referred to a neurologist who has placated the intense pain suffered by my father for 4 months...

Answer: Unfortunately, post-herpetic neuralgia frequently occurs with herpes zoster. The treatment for this type of pain ( that is, neuropathological pain) isnít easy. Certain drugs like tricyclic antidepressants, gabapentin, painkillers...

Research Projects


fareCentro Studi GISED has established Psonet, an international registry of systematic treatments for psoriasis in Europe...

Last update jan 13 2020  -  Centro Studi GISED  P.I. 02274270988 | Terms of use    Privacy    Credits

Back to content | Back to main menu
Facebook Twitter LinkedIn Email